Table 1.

Schedule and procedures during patient visits to the participating center.

Procedure	Enrollment phase (12 months)	Experimental phase (12 months)					Follow-up (6 months)
	Preliminary visit (369 to 3 days before the experimental phase)	First medical visit (day 0)	Hemodialysis sessions (approximately every 3 days)	Every 30 days	Weeks 13, 26, 39 and 52	Hemodialysis sessions (every 30 days)
Informed consent form	Xa
Physical exam/medical history and medication review	X
Inclusion/Exclusion	X
Collection of a blood sampleb		X			X
Randomization		X
Patients’ meeting with the study team and oral training about compliance to treatment		X		X
Provision of the necessary number of pills (on a monthly basis)		X		X
Patients’ training focused on compliance (short educative video)			X
Counting of returned pills				X
Blinding assessment (questionnaire)				X
Measurement of primary and secondary outcomesc during consultations with a nephrologist and a cardiologist		X			X
Assessment of later bleeding adverse events						X

^aX indicates the time at which each procedure will occur.

^bAssessment of the hematocrit, hemoglobin concentration, and platelet hyperreactivity profile.

^cNumber of events for cardiac death, nonfatal myocardial infarction, nonfatal stroke, arteriovenous fistula thrombosis, and assessment of major and minor bleeding using the Thrombolysis in Myocardial Infarction scale.